Casirivimab/imdevimab + remdesivir in hospitalized patients with severe Covid-19: A single centre experience

Since 2020, COVID-19 pandemic has spread worldwide causing a huge number of cases and casualties. Among direct anti SARS-CoV-2 agents available for the treatment of COVID-19, only remdesivir and casirivimab/imdevimab have been approved for severe disease. As they act at different levels in blocking...

Descripción completa

Detalles Bibliográficos
Autores principales: Moriello, Nicola Schiano, Buonomo, Antonio Riccardo, Scotto, Riccardo, Pinchera, Biagio, Sarno, Marina, Fusco, Ludovica, Viceconte, Giulio, Iuliano, Antonio, Zappulo, Emanuela, Foggia, Maria, Villari, Riccardo, Gentile, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859639/
https://www.ncbi.nlm.nih.gov/pubmed/36713627
http://dx.doi.org/10.1016/j.heliyon.2023.e13126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859639/
https://www.ncbi.nlm.nih.gov/pubmed/36713627
http://dx.doi.org/10.1016/j.heliyon.2023.e13126

Ejemplares similares